Comparison · NCT00558259-e8d15e44
Dabigatran vs Placebo: Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dabigatran vs Placebo: Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period. Trial comparisons, record NCT00558259-e8d15e44. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00558259-e8d15e44
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00147 | 0.000259 | 0.00827 | wilson | |
| Risk in group 2 | 0.0211 | 0.0126 | 0.0352 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0197 | -0.0338 | -0.00879 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.0694 | 0.00916 | 0.527 | log | |
| Odds ratio, group 1 over group 2 | 0.0681 | 0.00893 | 0.519 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dabigatran than on Placebo | 50.8 | 29.6 | 114 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dabigatran | Dabigatran 150mg bid | 1 | 681 | OG000 |
| Group 2 | Placebo | Matching placebo | 14 | 662 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Centrally Confirmed Symptomatic Pulmonary Embolism (PE) Events During the Intended Treatment Period
- Description
- Number of participants with centrally confirmed symptomatic pulmonary embolism (PE) events during the intended treatment period were described.
- Time frame
- 6 months
- Population
- FAS and analysed as randomised.
Source ClinicalTrials.gov
Trial
- Title
- Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
- NCT number
- NCT00558259
- Phases
- PHASE3
- Conditions
- Venous Thromboembolism
- Interventions
- dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID)
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2012-03-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00558259?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00558259-e8d15e44